Myeloma bone disease: Progress in pathogenesis

被引:6
|
作者
Xi, Hao [1 ]
An, Ran [1 ]
Li, Lu [1 ]
Wang, Gang [2 ]
Tao, Yi [3 ]
Gao, Lu [2 ]
机构
[1] Second Mil Med Univ, Changzheng Hosp, Myeloma & Lymphoma Ctr, Dept Hematol, Shanghai, Peoples R China
[2] Second Mil Med Univ, Dept Physiol, 800 Xiangyin Rd, Shanghai 200433, Peoples R China
[3] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Hematol, Shanghai, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
Myeloma bone disease; Osteoblast; Osteoclast; Osteoclast cell activating factor; Osteoblast cell inactivating factor; MULTIPLE-MYELOMA; OSTEOCLAST FORMATION; GROWTH-FACTOR; IN-VITRO; OSTEOBLAST DIFFERENTIATION; CELL-PROLIFERATION; TUMOR BURDEN; INHIBITION; ACTIVATION; EXPRESSION;
D O I
10.1016/j.pbiomolbio.2016.08.003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Myeloma bone disease (MBD) is one of the most serious complications of multiple myeloma (MM) and the most severe cause of MM morbidity. Dysregulation of osteoblast and osteoclast cells plays key roles in MBD. In the bone marrow microenvironment, myeloma cells, osteoblasts, osteoclasts and bone marrow stromal cells can secrete multiple cytokines, categorized as osteoclast cell activating factors (OAFS) and osteoblast cell inactivating factors, which have been discovered to participate in bone metabolism and contribute to the pathogenesis of MBD. Several signaling pathways related to these cytokines were also revealed in the MBD pathogenesis. To better understand the pathogenesis of MBD and therefore the potential therapeutic targets of this disease, we will summarize recent study progress in the factors and underlying signaling pathways involved in the occurrence and development of MBD. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:149 / 155
页数:7
相关论文
共 50 条
  • [1] Pathogenesis of myeloma bone disease
    Roodman, GD
    BLOOD CELLS MOLECULES AND DISEASES, 2004, 32 (02) : 290 - 292
  • [2] Pathogenesis of myeloma bone disease
    Roodman, G. D.
    LEUKEMIA, 2009, 23 (03) : 435 - 441
  • [3] Pathogenesis of myeloma bone disease
    G D Roodman
    Leukemia, 2009, 23 : 435 - 441
  • [4] Pathogenesis of Myeloma Bone Disease
    Roodman, G. David
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2010, 109 (02) : 283 - 291
  • [5] The pathogenesis of the bone disease of multiple myeloma
    Edwards, Claire M.
    Zhuang, Junling
    Mundy, Gregory R.
    BONE, 2008, 42 (06) : 1007 - 1013
  • [6] Pathogenesis and management of myeloma bone disease
    Christoulas, Dimitrios
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    EXPERT REVIEW OF HEMATOLOGY, 2009, 2 (04) : 385 - 398
  • [7] Pathogenesis and treatment of multiple myeloma bone disease
    Hiasa, Masahiro
    Harada, Takeshi
    Tanaka, Eiji
    Abe, Masahiro
    JAPANESE DENTAL SCIENCE REVIEW, 2021, 57 : 164 - 173
  • [8] Pathogenesis and Treatment of Myeloma-Related Bone Disease
    Gau, Yuh-Ching
    Yeh, Tsung-Jang
    Hsu, Chin-Mu
    Hsiao, Samuel Yien
    Hsiao, Hui-Hua
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (06)
  • [9] Myeloma bone disease: Pathogenesis and treatment - From the multiple myeloma research foundation
    Anderson, KC
    Roodman, GD
    ONCOLOGY-NEW YORK, 2005, 19 (08): : 983 - +
  • [10] Pathogenesis of bone disease in multiple myeloma: from bench to bedside
    Terpos, Evangelos
    Ntanasis-Stathopoulos, Ioannis
    Gavriatopoulou, Maria
    Dimopoulos, Meletios A.
    BLOOD CANCER JOURNAL, 2018, 8